Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-Expressing Neural Stem Cells with Flucytosine and Leucovorin for Recurrent High-Grade Gliomas
NCT02015819Phase 1Completed
- Sponsor
- City of Hope
- Start
- Oct 2014
- Primary completion
- Oct 2017
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of E. coli CD-expressing genetically modified neural stem cells in glioma, sponsored by City of Hope. Primary endpoints: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) and Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham. Started Oct 2014; status: completed.
02
Drugs
E. coli CD-expressing genetically modified neural stem cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02015819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015819.